Summary
You may be eligible if you have unresectable, locally advanced, or metastatic urothelial cancer, have a FGFR3 genetic alteration and have not had prior treatment for your advanced diesease. Prior treatment for an earlier stage disease is permitted.
The study includes a safety lead-in phase to evaluate the combination of vepugratinib, enfortumab vedotin, and pembrolizumab.
Once the safety and tolerability of this combination is confirmed, participants are then randomly assigned (by chance) to one of two treatment arms to receive either:
- Vepugratinib, enfortumab vedotin, and pembrolizumab
- Placebo, enfortumab vedotin, and pembrolizumab
Study participation could last up to approximately 6 years.